These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 20367564)

  • 1. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
    Czuczman MS; Gregory SA
    Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ofatumumab, a human anti-CD20 monoclonal antibody.
    Osterborg A
    Expert Opin Biol Ther; 2010 Mar; 10(3):439-49. PubMed ID: 20109133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel CD20 monoclonal antibodies for lymphoma therapy.
    Cang S; Mukhi N; Wang K; Liu D
    J Hematol Oncol; 2012 Oct; 5():64. PubMed ID: 23057966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obinutuzumab for B-cell malignancies.
    Owen CJ; Stewart DA
    Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.
    O'Brien S; Osterborg A
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):361-8. PubMed ID: 21030349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
    Cheson BD
    J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
    Reagan JL; Castillo JJ
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
    Barth MJ; Czuczman MS
    Future Oncol; 2013 Dec; 9(12):1829-39. PubMed ID: 24295413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ofatumumab for the treatment of chronic lymphocytic leukemia.
    Grosicki S
    Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
    Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
    Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.
    Jain P; O'Brien S
    Expert Opin Biol Ther; 2013 Feb; 13(2):169-82. PubMed ID: 23256681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical use of monoclonal antibodies in malignant lymphomas].
    Schnell R; Hiddemann W; Diehl V; Engert A
    Internist (Berl); 2001 Jun; 42(6):815-6, 819-26. PubMed ID: 11449628
    [No Abstract]   [Full Text] [Related]  

  • 17. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
    Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
    J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
    Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
    J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
    Milani C; Castillo J
    Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
    Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.